Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Sales and Divestitures: 2020-2024

Historic Gains from Sales and Divestitures for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $2.1 million.

  • Relay Therapeutics' Gains from Sales and Divestitures rose 140.52% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 140.52%. This contributed to the annual value of $2.1 million for FY2024, which is 140.52% up from last year.
  • Relay Therapeutics' Gains from Sales and Divestitures amounted to $2.1 million in FY2024, which was up 140.52% from $883,652 recorded in FY2023.
  • Over the past 5 years, Relay Therapeutics' Gains from Sales and Divestitures peaked at $2.1 million during FY2024, and registered a low of $84,489 during FY2021.
  • Its 3-year average for Gains from Sales and Divestitures is $1.1 million, with a median of $883,652 in 2023.
  • As far as peak fluctuations go, Relay Therapeutics' Gains from Sales and Divestitures tumbled by 85.43% in 2021, and later surged by 371.46% in 2022.
  • Yearly analysis of 5 years shows Relay Therapeutics' Gains from Sales and Divestitures stood at $579,825 in 2020, then plummeted by 85.43% to $84,489 in 2021, then skyrocketed by 371.46% to $398,330 in 2022, then skyrocketed by 121.84% to $883,652 in 2023, then surged by 140.52% to $2.1 million in 2024.